Non-invasive prenatal testing (NIPNT) in Jordan

Non-invasive prenatal testing (NIPT) is performed on a blood sample from the pregnant mother, examining fragments of fetal DNA that have crossed into her blood to estimate the likelihood of an abnormality in the number of certain chromosomes — most notably trisomy 21 (Down syndrome), 18 and 13, and it may include sex chromosomes. Its advantage is that it is **completely safe for the pregnancy**, because it is only a maternal blood draw — no needle enters the uterus — and its accuracy in estimating risk is far higher than traditional screening tests. It is usually performed from around the tenth week. But here is **the most important thing every pregnant woman must understand, and it is often explained imprecisely**: this is a **screening** test, not a diagnostic one. Its result is a probability, not a verdict: • A “low risk” result **does not exclude** every condition and does not mean a completely healthy fetus — it does not test for all genetic diseases or structural anomalies. • A “high risk” result **is not a confirmed diagnosis** — it requires confirmation with a diagnostic test (amniocentesis or chorionic villus sampling) before **any** decision. This distinction is not academic: life-changing decisions have been taken on unconfirmed screening results. False positives occur for known reasons including a chromosomal difference confined to the placenta, a twin pregnancy where one twin stopped developing, or conditions in the mother herself. The result may also come back **inconclusive** if the fetal DNA fraction is low — commoner with higher weight or very early testing — and is then repeated. The test should therefore be accompanied by **genetic counselling** explaining its meaning before the draw and after the result, and it is optional, decided by the mother after understanding it.